308P Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

Abstract

The standard of treatment for patients with unresectable, locally advanced NSCLC (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although phase II studies in Japan have shown high efficacy and good tolerability of CRT with cisplatin + S-1 (SP), no prospective study using durvalumab after SP-based CRT has been reported. Thus, we conducted a phase II study using durvalumab after SP-based CRT for LA-NSCLC. The primary analysis was already presented in IASLC Asia 2022. Here, we report the additional results.